Literature DB >> 9051327

Malignant melanoma in Europe: changes in mortality rates (1970-90) in European Community countries.

D Balzi1, P Carli, M Geddes.   

Abstract

Reducing mortality, especially premature death, is a major goal of the fight against cancer. In this study, we have analyzed trends in malignant melanoma (MM) mortality in the European Community (EC) as a whole and for each country. The data (obtained from the World Health Organization data bank) have been analyzed for the period 1970-90, by age groups (20-44, 45-64, 65-74, 75+ years). Trends are presented as percentage change of mortality rate for each three-year period in comparison with the rate in the first one (1970-72). The mortality from MM in the EC as a whole increased for both genders (men, +89.2 percent; women, +72.6 percent), with statistically significant trends in all age classes. Northern countries experienced mortality changes about 30 to 50 percent less than the EC average increase. Greater changes were seen in southern European countries, in which recent standardized rates are near to those observed in northern European populations. Among Mediterranean people, the highest increase (more than fourfold) was observed in Spain. The significant increase found for the younger age class makes unlikely the risk of misclassification with other skin cancers. No future decrease in MM mortality in the EC is indicated from these data.

Entities:  

Mesh:

Year:  1997        PMID: 9051327     DOI: 10.1023/a:1018491323442

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  2 in total

1.  Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985-1992.

Authors:  R Ocaña-Riola; C Martinez-Garcia; S Serrano; A Buendía-Eisman; C Ruiz-Baena; J Canela-Soler
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

2.  Mortality from cutaneous melanoma: evidence for contrasting trends between populations.

Authors:  G Severi; G G Giles; C Robertson; P Boyle; P Autier
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.